100+ Active Companies working to develop 100+ Pipeline Therapies for PI3K Inhibitors Treatment Landscape

April 06 13:58 2023
100+ Active Companies working to develop 100+ Pipeline Therapies for PI3K Inhibitors Treatment Landscape

DelveInsight’s, “PI3K inhibitors Pipeline Insights 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the PI3K Inhibitors pipeline drug profiles, including PI3K Inhibitors clinical trials and nonclinical stage products. It also covers the PI3K Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For PI3K inhibitors Emerging drugs, the PI3K inhibitors pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The PI3K inhibitors pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the PI3K inhibitors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, PI3K inhibitors clinical trials studies, PI3K inhibitors NDA approvals (if any), and product development activities comprising the technology, PI3K inhibitors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the PI3K inhibitors Pipeline Report

 

  • DelveInsight’s PI3K Inhibitors Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for PI3K Inhibitors treatment.

 

  • The leading PI3K Inhibitors Companies include TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, Bayer, and others.

 

  • Promising PI3K Inhibitors Pipeline Therapies include Copanlisib (BAY80-6946), Rituximab, and others.

 

  • The PI3K Inhibitors Companies and academics that are working to assess challenges and seek opportunities that could influence PI3K Inhibitors R&D. The PI3K Inhibitors pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the PI3K Inhibitors Pipeline treatment landscape of the report, click here @ PI3K Inhibitors Pipeline Outlook

 

PI3K Inhibitors Overview

Phosphatidylinositol-3 kinases (PI3Ks) are lipid kinases that phosphorylate signaling lipid PIP2 to PIP3. PIP3 molecules recruit proteins bearing PIP3-binding pleckstrin homology (PH) domains such as Akt in the PI3K/Akt/mTOR signaling pathway to the plasma membrane. The PI3K pathway is among the most frequently activated in human cancers, impacting almost 50% of the malignancies.

 

Recent Developmental Activities in the PI3K Inhibitors Treatment Landscape

 

  • Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.

 

  • Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.

 

  • YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.

  

For further information, refer to the detailed PI3K Inhibitors Unmet Needs, PI3K Inhibitors Latest Drugs Launch News and Breakthroughs, click here for PI3K Inhibitors Ongoing Clinical Trial Analysis

 

PI3K Inhibitors Emerging Drugs Profile

 

  • Umbralisib: TG Therapeutics

Umbralisib (TGR-1202) is an oral, once daily, dual inhibitor of PI3K delta and CK1 epsilon. Umbralisib has nanomolar potency to the delta isoform of PI3K and high selectivity over the alpha, beta, and gamma PI3K isoforms. Umbralisib also uniquely inhibits casein kinase 1 epsilon (CK1 epsilon), which may have both direct anti-cancer effects and may also modulate T-cell activity associated with immune-mediated adverse events seen with previous PI3K inhibitors. Currently, umbralisib is being evaluated in Phase IIb and Phase III trials in patients with NHL and CLL.

 

  • Gedatolisib: Pfizer

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Pfizer. It works by targeting PI3K/mTOR. The Phase II clinical trials of gedatolisib for treatment of endometrial cancer and colorectal cancer were terminated early due to enrollment issues. It is currently in phase II stage of development.

 

  • Parsaclisib: Incyte Corporation

Parsaclisib is a potent, highly selective, next-generation PI3Kδ inhibitor that is not associated with clinically meaningful transaminitis. It is in phase II stage of development.

 

  • YH 25248: Yuhan

YH 25248 is an oral selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, being developed by Yuhan, for the treatment of cancer.

 

PI3K Inhibitors Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies based on PI3K inhibitors. The companies which have their drug candidate based on PI3K inhibitors in the most advanced stage, i.e. phase II/III include TG Therapeutics and others

 

Request a sample and discover the recent advances in PI3K Inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ PI3K Inhibitors Treatment Landscape Analysis

 

Scope of the PI3K Inhibitors Pipeline Report

 

  • Coverage- Global

 

  • PI3K Inhibitors Companies- TG Therapeutics, Pfizer, Incyte Corporation, Yuhan, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, Bayer, and others.

 

  • PI3K Inhibitors Pipeline Therapies- Copanlisib (BAY80-6946), Rituximab, and others.

 

  • PI3K Inhibitors Pipeline Segmentation: Product Type, Molecule Type, Route of Administration 

 

Dive deep into rich insights for drugs for PI3K Inhibitors Market Drivers and PI3K Inhibitors Market Barriers, click here @ PI3K Inhibitors Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. PI3K inhibitors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. PI3K inhibitors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. PI3K inhibitors Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Umbralisib: TG Therapeutics
  11. Mid Stage Products (Phase II)
  12. Gedatolisib: Pfizer
  13. Parsaclisib: Incyte Corporation
  14. Early Stage Products (Phase I)
  15. Drug Name: Company Name
  16. Pre-clinical and Discovery Stage Products
  17. YH 25248: Yuhan
  18. Inactive Products
  19. PI3K inhibitors Key Companies
  20. PI3K inhibitors Key Products
  21. PI3K inhibitors- Unmet Needs
  22. PI3K inhibitors- Market Drivers and Barriers
  23. PI3K inhibitors- Future Perspectives and Conclusion
  24. PI3K inhibitors Analyst Views
  25. PI3K inhibitors Key Companies
  26. Appendix

 

Got Queries? Find out the related information on PI3K Inhibitors Mergers and acquisitions, PI3K Inhibitors Licensing Activities @ PI3K Inhibitors Emerging Drugs, and Recent Trends

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/